Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Combo PharmaASX:S66 35 5-Year Yield-on-Cost % is 2.85 as of Aug. 02, 2026, which is 48% above its 10-year median of 1.93. GuruFocus rates ASX:S66 with a GF Score™ of 35/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,169 Consumer Packaged Goods companies, Star Combo Pharma ranks worse than 56.37% on this metric.
Star Combo Pharma's yield on cost for the quarter that ended in Dec. 2025 was 2.85.
The historical rank and industry rank for Star Combo Pharma's 5-Year Yield-on-Cost % or its related term are showing as below:
ASX:S66'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.54 Med: 1.93 Max: 3.64
Current: 2.85
During the past 9 years, Star Combo Pharma's highest Yield on Cost was 3.64. The lowest was 1.54. And the median was 1.93.
ASX:S66's 5-Year Yield-on-Cost % is ranked worse than 56.37% of 1169
companies
in the Consumer Packaged Goods industry
Industry Median: 3.42
vs ASX:S66: 2.85
Star Combo Pharma (ASX:S66) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Star Combo Pharma 5-Year Yield-on-Cost % Related Terms
ASX:S66 vs PG, CL, KVUE: 5-Year Yield-on-Cost % Comparison
For the Household & Personal Products subindustry, Star Combo Pharma's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Combo Pharma 5-Year Yield-on-Cost % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Star Combo Pharma's 5-Year Yield-on-Cost % falls into.
Star Combo Pharma 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Star Combo Pharma (ASX:S66) has a 5-Year Yield-on-Cost % of 2.85 as of Aug. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Star Combo Pharma and its competitors. This is 48% above median its historical median of 1.93. Over the past decade, Star Combo Pharma's 5-Year Yield-on-Cost % has ranged from 1.54 to 3.64. According to the industry distribution chart, Star Combo Pharma ranks #659 out of 1169 companies in the Consumer Packaged Goods industry, placing it in the top 56.4%.
Is Star Combo Pharma's 5-Year Yield-on-Cost % too high?
Star Combo Pharma's current 5-Year Yield-on-Cost % of 2.85 is 48% above median its 10-year median of 1.93. Over the past 10 years, this metric has ranged from a low of 1.54 to a high of 3.64. The Consumer Packaged Goods industry median 5-Year Yield-on-Cost % is 3.42. Star Combo Pharma's value of 2.85 is 16.7% below this industry median. Based on the distribution chart, Star Combo Pharma ranks #659 out of 1169 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Star Combo Pharma has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's 5-Year Yield-on-Cost % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Star Combo Pharma ranks #659 out of 1169 companies for 5-Year Yield-on-Cost %. This places Star Combo Pharma in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.42. Star Combo Pharma's value of 2.85 is 16.7% below this benchmark. Historically, Star Combo Pharma's own 5-Year Yield-on-Cost % has ranged from 1.54 to 3.64 over the past decade. While the company's 10-year median is 1.93 vs. the industry median of 3.42, Star Combo Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Consumer Packaged Goods company?
The median 5-Year Yield-on-Cost % among Consumer Packaged Goods companies is 3.42, based on 1,169 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Combo Pharma's current 5-Year Yield-on-Cost % of 2.85 is 16.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Star Combo Pharma and its competitors. For the Consumer Packaged Goods industry, the median 5-Year Yield-on-Cost % is 3.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Combo Pharma's current 5-Year Yield-on-Cost % is 2.85, which is 48% above median its own 10-year median of 1.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.13 — trading right at its estimated fair value. The current 5-Year Yield-on-Cost % is 2.85, which is 48% above median its 10-year median of 1.93 and 16.7% below the Consumer Packaged Goods industry median of 3.42. Star Combo Pharma's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current 5-Year Yield-on-Cost % is 2.85 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Combo Pharma (ASX:S66) Overvalued in 2026?
Based on GuruFocus' analysis, Star Combo Pharma stock appears to be undervalued.
The current stock price of A$0.13 is trading 0% below its estimated GF Value™ of A$0.13.
GuruFocus considers Star Combo Pharma to be Fairly Valued.
Key valuation signals for ASX:S66:
5-Year Yield-on-Cost %: 2.85 (48% above median its 10-year median of 1.93)
GF Value™: A$0.13 vs. price of A$0.13 (0% below fair value)
Industry Position: 16.7% below the Consumer Packaged Goods median (#659 of 1169)
No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
35GF Score
Get the complete analysis for ASX:S66
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:S66 has been successfully added to your 
